Feeds:
Posts
Comments
The Thomson Reuters Extel 2012 Investor Relations North America study has begun!

I invite you and your IR team to take part in the first Thomson Reuters Extel Investor Relations study for North America.

Voting runs until July 1st, 2012.

To take part –

Online at www.extelsurveys.com (Log in with your email address & your password; then click on the VOTE NOW button or

By email: please request an interactive PDF questionnaire which you can return to us by email or fax

Why take the survey?

Every company taking part will get a complimentary copy of the Executive Summary report, giving you the highlights on the key trends in IR, and what the buy-side and sell-side are really looking for from IR teams.

And one lucky winner will win a new Apple iPad!

I do hope you will be able to take part in the Survey, and please let me know at any time if you have questions or concerns.

Thank you and regards,

The Extel Team

extelsurveys@thomsonreuters.com

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of May 7– May 11, 2012

Sector gains outpaced those in major US averages. A series of positive regulatory rulings and clinical read-outs provided industry-specific strength. Mid-cap company earnings, several of which provided visibility into drug launch progress, were mixed. For the week, the BTK climbed 4.14% to 1511.91, and the NBI rose 3.83% to 1313.48.

 

REGULATORY

Pfizer announced on Wednesday the Arthritis Advisory Committee to the FDA voted 8-2 to recommend approval of tofacitinib in adult patients with moderately to severely active RA. The FDA has provided an anticipated PDUFA action date in August 2012. Pfizer rose 1.13% at $22.45.

Reuters reported an experimental obesity pill from Arena Pharmaceuticals won a U.S. panel’s support. A panel of outside experts to the FDA voted 18 to 2, with one abstention, to recommend approval of lorcaserin. The FDA will make a final decision by June 27. Arena soared 73.77% to $6.36 on Friday. Continue Reading »

The Thomson Reuters Extel 2012 Investor Relations North America study has begun!

I invite you and your IR team to take part in the first Thomson Reuters Extel Investor Relations study for North America.

Voting runs from April 30th to May 25th, 2012.

To take part –

Online at www.extelsurveys.com (Log in with your email address & your password; then click on the VOTE NOW button or

By email: please request interactive PDF questionnaire which you can return to us by email or fax

Why take the survey?

Every company taking part will get a complimentary copy of the Executive Summary report, giving you the highlights on the key trends in IR, and what the buy-side and sell-side are really looking for from IR teams.

One lucky winner will win an iPad!

I do hope you will be able to take part in the Survey, and please let me know at any time if you have questions or concerns.

Thank you and regards,

 

Extel team

 

 Contact details:

 

extelsurveys@thomsonreuters.com

 

Tel. +44 (0) 20 7542 7700

 

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of Apr. 30– May 4, 2012

Sector indices fell with major US averages. For the week, the BTK declined 1.96% to 1451.84, and the NBI slipped 3.36% to 1265.03.

 

REGULATORY

Reuters reported on Thursday GlaxoSmithKline and Human Genome Sciences’ lupus drug Benlysta was rejected by Germany’s healthcare cost watchdog. The negative draft benefit assessment from the German Institute for Quality and Efficiency in Health Care follows a similar rebuff from Britain’s NICE. Glaxo rose 0.47% to $46.89, and Human Genome rose 0.28% to $14.55.

Alexza Pharmaceuticals announced it received a CRL from the FDA regarding its NDA for ADASUVE inhalation powder, 5 mg and 10 mg. ADASUVE is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Alexza fell 19.67% to $0.49 on Friday. Continue Reading »

“The future ain’t what it used to be” – Yogi Berra  

 What’s the market telling us?

According to the Thomson Reuters proprietary research team, of the 275 S&P 500 companies that have reported Q1 2012 earnings thus far, 72% have beat analysts’ expectations. While this number is considerably higher than the long-term average of 62%, share performance on earnings days has told a remarkably different story. With an average one-day share gain of 0.47% and individual stock fluctuation scattered anywhere between -29% to +52%, we have found that accounting for market expectations going into an event allows us to predict how a stock will perform post earnings release. By understanding the tools that investors utilize to predict market moves on scheduled corporate events, such as earnings releases, Investor Relations Officers (IRO’s) can gain insight to how the market is positioning. Therefore, this creates an opportunity to better prepare and cushion expectations leading up to the market moving events.

Continue Reading »

Corporate communications professionals are publishing their own content every day: tweets, blog posts, email announcements, website copy, Facebook posts (to name just a few). Yet most still rely on a third party wire service to review and publish their regulatory and press releases—and they’re paying for it. Many are looking for an alternative to this time consuming and often costly process.

Constellation Brands—the world’s leading premium wine producer—has implemented such an alternative using a secure self-publishing tool from Thomson Reuters. They now have full control of their releases from start to finish and are reallocating the cost-savings toward other activities such as measurement.

“The Thomson Reuters release publishing solution helps us meet our SEC disclosure requirements through a secure process,” said Patty Yahn-Urlau, Vice President of  Investor Relations at Constellation Brands. 

Read the case study to learn more, and let us know how you’re optimizing your disclosure process.

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of Apr. 23– Apr. 27, 2012

Sector indices advanced with earnings in focus. Gains in the BTK and NBI exceeded those in the major US averages. For the week, the BTK advanced 3.51% to 1480.90, and the NBI climbed 3.33% to 1308.96.

 

REGULATORY

Reuters reported on Friday U.S. health regulators approved Vivus’ Avanafil treatment for erectile dysfunction. Vivus gained 2.95% to $25.15. 

Amgen announced on Friday the FDA has issued a CRL for the sBLA for XGEVA (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases.  The FDA determined that the effect on bone metastases-free survival was of insufficient magnitude to outweigh the risks (including osteonecrosis of the jaw) of XGEVA in the intended population, and requested data from an adequate and well-controlled trial(s) demonstrating a favorable risk-benefit profile for XGEVA that is generalizable to the U.S. population. Amgen climbed 1.20% to $71.64. Continue Reading »

Wanted: High Quality, Liquid Companies at Reasonable Prices!

Mutual fund managers have been taking advantage of current low valuations and elevated levels of uncertainty to buy into liquid, solid companies with attractive levels of financial returns and strong balance sheets.

The current market is an exceptionally difficult one for money managers and – by extension – for Investor Relations Officers (IROs) who are trying to communicate their investment story. But despite the challenges of uncertainly, low growth, high correlations and low volumes (to name a few) there are still stocks that are being invested in.

We looked into the types of stocks which are being bought by mutual fund managers – focusing on the financial characteristics – or fundamentals – of those stocks, such as Return on Assets (ROA), PE, EV/EBITDA and so forth.

Diving a little more into how we conducted the analysis:

  • We analyzed stocks acquired in the first-quarter of 2012, in other words we ignored the sells and the holds in the portfolio
  • We looked at 25,000 mutual fund portfolios globally
  • We identified the 24 financial characteristics of each of the stocks bought and used these to identify what the fund manager was screening for (for example, how often did ROA above a certain threshold appear in that fund manager’s stock selection?)
  • Having identified which fundamental factors are most important to mutual fund managers’ stock selection process, we looked at which are the most commonly occurring factors.

What are the results?  Having crunched the numbers, this is what we found about the fund manager’s selection criteria:

  • Trading volumes are the most important screen! Although not strictly a fundamental characteristic, like ROA or EV/EBITDA, volumes are the most important gating factor in a fund manager’s stock selection process. This chimes with comments that we hear from the buy-side right now. With trading volumes so low, investors are concerned about their ability to get into a stock – and crucially get out of it – without impacting the share price too much
  • Solid financial returns are critical. Investors are looking for companies with attractive financial returns, buying stocks with relatively high Return On Equity (ROE at least 6.4%) and attractive Return on Assets (ROA at least 7.8%). Net profit margins need to be solid, at least 3.5%
  • Investors are also looking for some of the cash generated to be returned.  Delivering financial returns alone is not enough. Portfolio managers are typically screening for stocks that have a historic dividend yield of 1%. Around one third of the time investors are also screening for the forecast dividend yields, typically looking for one year projected yields of approximately 1.5%.
  • Leverage is an important gating factor, but occurring less commonly than during the depths of the financial crisis. The metric that investors are focused on is interest coverage (EBIT/Interest expense) which is a good indicator of a firm’s ability to meet its financial obligations. Investors are typically looking for companies with a healthy 2.8x interest cover.
  • Valuation is important, but not a critical factor.  Surprisingly, valuation is not as important as one would have thought, indicating that portfolio managers are more focused on scooping up quality companies than just focusing on the cheapest stocks. Among other valuation measures, we used a metric that ranks all companies from 1 to 100 (with 1 being the most expensive and 100 the best value), based on six measures, including EV/Sales, PE and Price/ Cash Flow*. Investors are typically buying companies ranked 35 and above, indicating that they’re focused on reasonable value stocks, but not necessarily the cheapest.
  • Investors not very focused on growth. Just as interesting as what investors screen for is what investors are seldom looking for. Despite the internal focus within most companies on delivering growth, the simple fact is that most investors currently just aren’t that focussed on it when it comes to screening for stocks. For example, only 12% of the time the buy-side looking at future revenue growth when assessing which companies to buy. And even here the bar is set pretty low at just 1-2% forecast top-line growth.

Wanted: high quality, liquid companies at reasonable prices! Getting investors to act in current markets is no mean feat, but active investment decisions are being made despite the market turbulence. Mutual fund managers are focusing on finding high quality companies, as evidenced by their financial returns, dividend yield, ability to cover their debt repayments and trading at valuations that are reasonable, but not necessarily cheap. But given current low market volumes, the ability to trade in and out easily remains their number one concern.

 *The Thomson Reuters StarMine Relative Valuation model features six prominent valuation measures that are relevant to most securities: EV/Sales, EV/EBITDA, P/E, Price/CFO, Price/Book, and Dividend Yield. For companies that do not pay dividends, the model also considers share buyback activity.

Dividend growth strong in both the long and short term – S&P 500 companies witnessed strong dividend growth over the past few years despite global economic uncertainty – the dollar value of positive actions has nearly quadrupled since 2009 and surpassed 2007 levels by 35%.

This isn’t only a long-term trend – the most recent data shows that within the S&P 500, $11 billion dollars more was paid out in dividends in March 2012 versus February 2012, and $40 billion more than in March 2011. To put this into further context, 314 (or more than 62%) of the S&P 500 constituents have increased their dividends over the past 12 months.

Cash accumulating – But even with increased dividend payouts, cash has continued to build on corporate balance sheets, reaching the highest levels since 2004, as a percentage of total assets.

Income-oriented funds attract inflows while broadly active funds suffer – While cash continues to pile up on the sidelines, investors have been betting there will be even more cash returned to stockholders. Lipper fund flow data for 2011 and early 2012 shows that while actively-managed equity funds suffered heavy redemptions, flows into income- oriented funds, have been consistently positive over the same period and now account for around 14% of total active mutual fund money.

There is also strong statistical evidence that broader styles of funds are increasingly focused on dividend yield as a factor in their investment process.

With companies paying out more in dividends and dividend-focused funds with more money to put to work, there are clearly opportunities for companies to market their story to investors.

Understanding the addressable market is key – an analysis of all mutual funds’ dividend yield preferences demonstrates that the overall addressable investor market grows considerably for companies that have dividend yields of about 2%.

If we analyze dividend yields from 2% to around 3.5%, the pace of that growth slows but the addressable market is still significant. And if your company is paying a dividend with a yield above 3.5%, the numbers show that, while individual fund preferences for yield and other investment characteristics naturally differ, there are very few examples left where your dividend yield would risk exclusion altogether from a portfolio.

For many investor relations teams whose companies have either recently changed their dividend policies or are likely to do so imminently, the question all IROs should ask is, “How can we maximize the opportunities available with income-focused funds?”

To hear our thoughts around this question and more on the trends described above you can now watch the webinar, download the presentation and our Rising Dividend study at your convenience.

Put the latest biotech news in context with this week’s Biotech Commentary report, generated by Thomson Reuters IR Advisory Services analysts.  Learn about relevant clinical and regulatory news, information on partnerships and financings, notable sell-side upgrades, downgrades and price target changes, earnings recaps, and informative sector articles and videos.  Read the report.  Interested in getting similar commentaries on a daily basis – before the market opens and following the close?  Leave a comment to let us know.

 

Week of Apr. 16– Apr. 20, 2012

Sector indices outperformed majorUSaverages, fueled late in the week by M&A newsflow and clinical pipeline updates at EASL. For the week, the BTK rallied 8.10% to 1430.56, and the NBI climbed 3.24% to 1266.72.

 

REGULATORY

AstraZeneca and Bristol-Myers Squibb announced the CHMP recommended the approval of FORXIGA (dapagliflozin) tablets for the treatment of Type II diabetes, as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products including insulin, and as a monotherapy in metformin intolerant patients. AstraZeneca gained 1.83% to $38.73 on Friday, and Bristol-Myers Squibb rose 0.88% to $34.23.

Novartis announced the CHMP adopted a positive opinion for Jakavi (INC424, ruxolitinib) for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. In addition, the company announced that the CHMP confirmed a positive benefit-risk profile of once-daily oral Gilenya (fingolimod). Novartis and the CHMP have agreed to recommended updates to the product information in the EU in order to provide further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients. Novartis rose 1.64% to $56.38 on Friday. Continue Reading »